FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2371-2373 November 30, 2006 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Psaty, B. M. Related Article by Bertagnolli, M. M. Related Article by Arber, N. PubMed Citation

To the Editor: In the article by Arber et al. (Aug. 31 issue)¹ about the Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) trial, the percentage of patients with the combined end point of adjudicated serious cardiovascular events did not differ significantly between the celecoxib and placebo groups. Using data from Supplementary Appendix 2, we calculate that the rate ratio for "cardiac disorders" (including myocardial infarction) is 1.6 (95% confidence interval [CI], 0.9 to 2.8), whereas for "nervous system disorders" (including stroke), it is 0.7 (95% CI, 0.4 to 1.3). Similar results were reported by Bertagnolli et al.² in the Supplementary . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.